Form 4: ProMIS Neurosciences Director Madge K. Shafmaster Acquires Options

Director Madge K. Shafmaster acquired options to purchase 40,000 common shares of ProMIS Neurosciences Inc. on October 3, 2024.

Summary

• On October 3, 2024, Madge K. Shafmaster, a director of ProMIS Neurosciences Inc., acquired options to purchase 40,000 common shares.
• The exercise price of the options is $1.11.
• 33% of the options vested immediately on October 3, 2024, with the remaining balance vesting ratably over the next 24 months, contingent upon continued service.
• The options expire on October 3, 2034.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing an option grant to a director. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Future Outlook

The remaining options will vest ratably over the following 24 months, subject to the Reporting Person's continued service on each such vesting date.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology sector.

Stakeholder Impact

• The option grant aligns the director's interests with those of the shareholders, as the value of the options is tied to the company's stock performance.

Key Dates